Patients on Ozempic and Wegovy can lose 15 to 20 percent or more of their weight in a little over a year, with lasting results.
GLP-1 drugs cut risk of heart attacks, strokes, and death from coronary disease by 20 percent among overweight and obese patients, potentially through weight loss effects.
Semaglutide has shown to reduce the need for insulin in recent-onset Type 1 diabetes and significantly reduce kidney disease progression and death rates in Type 2 diabetes patients.
[
add
]
[
|
|
...
]